Cyclacel Pharmaceuticals - 48 Year Dividend Yield History | CYCC

Historical dividend payout and yield for Cyclacel Pharmaceuticals (CYCC) since 1971. The current TTM dividend payout for Cyclacel Pharmaceuticals (CYCC) as of February 21, 2019 is $0.00. The current dividend yield for Cyclacel Pharmaceuticals as of February 21, 2019 is 0.00%.
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.010B $0.001B
CYCLACEL is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. Three orally-available Cyclacel drugs are in clinical development. Sapacitabine, a cell cycle modulating nucleoside analog, is in Phase 2 studies for the treatment of acute myeloid leukemia in the elderly, myelodysplastic syndromes and cutaneous T-cell lymphoma. Seliciclib (CYC202 or R-roscovitine), a CDK inhibitor, is in Phase 2 for the treatment of lung cancer and nasopharyngeal cancer.
Stock Name Country Market Cap PE Ratio
Amgen (AMGN) United States $116.316B 12.97
Gilead Sciences (GILD) United States $86.647B 10.87
Bio-Techne Corp (TECH) United States $7.316B 49.29